US 12,458,628 B2
Cancer therapeutic
Hitoshi Endou, Yokohama (JP); Junji Furuse, Mitaka (JP); Isao Okayasu, Tokyo (JP); and Michael F. Wempe, Aurora, CO (US)
Assigned to J-PHARMA CO., LTD., Yokohama (JP)
Appl. No. 16/957,293
Filed by J-Pharma Co., Ltd., Yokohama (JP)
PCT Filed Aug. 1, 2018, PCT No. PCT/JP2018/028887
§ 371(c)(1), (2) Date Jun. 23, 2020,
PCT Pub. No. WO2019/130637, PCT Pub. Date Jul. 4, 2019.
Claims priority of application No. 2017-253385 (JP), filed on Dec. 28, 2017.
Prior Publication US 2020/0405695 A1, Dec. 31, 2020
Int. Cl. A61K 31/423 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/423 (2013.01) [A61P 35/00 (2018.01)] 11 Claims
 
1. A method for treating solid cancer, comprising:
administering O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-L-tyrosine or a pharmacologically acceptable salt thereof at 1 mg/m2 to 40 mg/m2 once daily by intravenous injection to a human patient in need thereof,
wherein the solid cancer is bile duct cancer, colorectal cancer, esophageal cancer, breast cancer, or pancreatic cancer.